These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 18092420)

  • 1. Levonorgestrel-releasing intrauterine device and uterine perforations.
    Prescrire Int; 2007 Dec; 16(92):248-9. PubMed ID: 18092420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of levonorgestrel-releasing intrauterine system (LNG-IUS) uterine perforation.
    Margarit LM; Griffiths AN; Vine SJ
    J Obstet Gynaecol; 2004 Aug; 24(5):586-7. PubMed ID: 15369954
    [No Abstract]   [Full Text] [Related]  

  • 3. [Abdominal migration of a levonorgestrel-releasing intrauterine device. Case report and review of the literature].
    Pont M; Lantheaume S
    J Gynecol Obstet Biol Reprod (Paris); 2009 Apr; 38(2):179-81. PubMed ID: 19303222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer.
    Neven P; Amant F; Poppe W; Van den Broecke R
    Fertil Steril; 2009 Apr; 91(4):e5; author reply e6. PubMed ID: 19249759
    [No Abstract]   [Full Text] [Related]  

  • 5. Uterine perforation in women using a levonorgestrel-releasing intrauterine system.
    Van Houdenhoven K; van Kaam KJ; van Grootheest AC; Salemans TH; Dunselman GA
    Contraception; 2006 Mar; 73(3):257-60. PubMed ID: 16472566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal levonorgestrel-releasing intrauterine device following uterine perforation: the role of progestins in adhesion formation.
    Haimov-Kochman R; Doviner V; Amsalem H; Prus D; Adoni A; Lavy Y
    Hum Reprod; 2003 May; 18(5):990-3. PubMed ID: 12721174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):274-9. PubMed ID: 25601352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmural migration and perforation of a levonorgestrel intrauterine system: a case report and review of the literature.
    Ferguson CA; Costescu D; Jamieson MA; Jong L
    Contraception; 2016 Jan; 93(1):81-6. PubMed ID: 26386445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uterine perforation with the levonorgestrel-releasing intrauterine device: analysis of reports from four national pharmacovigilance centres.
    van Grootheest K; Sachs B; Harrison-Woolrych M; Caduff-Janosa P; van Puijenbroek E
    Drug Saf; 2011 Jan; 34(1):83-8. PubMed ID: 21142273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mirena--the first intrauterine contraceptive therapeutic system].
    Rachev E
    Akush Ginekol (Sofiia); 2001; 40 Suppl 6():3-6. PubMed ID: 11803883
    [No Abstract]   [Full Text] [Related]  

  • 11. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study.
    Barnett C; Moehner S; Do Minh T; Heinemann K
    Eur J Contracept Reprod Health Care; 2017 Dec; 22(6):424-428. PubMed ID: 29322856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case of the lost Mirena.
    Tsimpanakos I; Moustafa M; Gkoutzioulis A; Mohamed M; Magos A
    J Obstet Gynaecol; 2011 Aug; 31(6):552-3. PubMed ID: 21823870
    [No Abstract]   [Full Text] [Related]  

  • 13. Cervical perforation by the strings of a levonorgestrel releasing-intrauterine system: a case report.
    Gönenç I; Vural EZ; Aka N
    Eur J Contracept Reprod Health Care; 2013 Oct; 18(5):415-8. PubMed ID: 23937289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe seborrhoeic dermatitis: side-effect of the Mirena intra-uterine system.
    Karri K; Mowbray D; Adams S; Rendal JR
    Eur J Contracept Reprod Health Care; 2006 Mar; 11(1):53-4. PubMed ID: 16546818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in Sweden.
    Marions L; Lövkvist L; Taube A; Johansson M; Dalvik H; Øverlie I
    Eur J Contracept Reprod Health Care; 2011 Apr; 16(2):126-34. PubMed ID: 21417562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system.
    Peloggia A; Petta CA; Bahamondes L; Oliveira-Ribeiro M; Zhang J; Salamonsen L
    Hum Reprod; 2006 May; 21(5):1129-34. PubMed ID: 16436495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levonorgestrel intrauterine device (IUD) exacerbation of PMS symptoms.
    Appiani FJ; Carroll BT
    Ann Clin Psychiatry; 2014 May; 26(2):146-7. PubMed ID: 24812652
    [No Abstract]   [Full Text] [Related]  

  • 18. Uterine perforation and laparoscopic retrieval of a levonorgestrel intrauterine system (Mirena).
    Selo-Ojeme DO; Ekong ME; Welch CC
    J Obstet Gynaecol; 2003 Jul; 23(4):445-6. PubMed ID: 12881099
    [No Abstract]   [Full Text] [Related]  

  • 19. Levonorgestrel-releasing intrauterine system: uses and controversies.
    Bahamondes L; Bahamondes MV; Monteiro I
    Expert Rev Med Devices; 2008 Jul; 5(4):437-45. PubMed ID: 18573044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine arteriovenous fistula after perforation during the placement of an intrauterine device - Minimally invasive treatment using uterine artery embolization.
    Kondo W; Tessmann Zomer M ; Erzinger FL
    Clin Exp Obstet Gynecol; 2016; 43(4):602-605. PubMed ID: 29734558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.